

Irl B Hirsch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7983159/publications.pdf>

Version: 2024-02-01

177
papers

16,944
citations

47409

49
h-index

17891

125
g-index

180
all docs

180
docs citations

180
times ranked

13764
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of Effects of Continuous Glucose Monitoring on Physical Activity Habits and Blood Lipid Levels in Persons With Type 1 Diabetes Managed With Multiple Daily Insulin Injections: An Analysis Based on the GOLD Randomized Trial (GOLD 8). <i>Journal of Diabetes Science and Technology</i> , 2024, 18, 89-98.	1.3	2
2	Comparing clinical outcomes between two continuous glucose monitors: similar diabetes-related events, all-cause hospitalizations and HbA1c reductions in type 1 and type 2 diabetes. , 2023, 9, 100008.		0
3	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1226-1242.	1.3	69
4	Glycaemic management in diabetes: old and new approaches. <i>Lancet Diabetes and Endocrinology</i> , the, 2022, 10, 75-84.	5.5	50
5	Diabetes and the WHO Model List of Essential Medicines. <i>Lancet Diabetes and Endocrinology</i> , the, 2022, 10, 16-17.	5.5	3
6	Ranting in 2022: Not More of the Same. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 81-83.	2.4	1
7	Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes. <i>Diabetes Care</i> , 2022, 45, 585-593.	4.3	1
8	Identifying Suicide Risk in Adolescents and Young Adults With Type 1 Diabetes: Are Depression Screeners Sufficient?. <i>Diabetes Care</i> , 2022, 45, 1288-1291.	4.3	8
9	Effect of liraglutide on markers of insulin production in persons with type 2 diabetes treated with multiple daily insulin injections. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108110.	1.2	1
10	The relationship between hypoglycaemia and glucose variability in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 733-736.	2.2	2
11	New Medications for the Treatment of Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, S-190-S-208.	2.4	0
12	Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108204.	1.2	15
13	How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 System. <i>Diabetes Research and Clinical Practice</i> , 2022, 190, 109998.	1.1	15
14	A new look at brittle diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107646.	1.2	18
15	Smoking is Associated With Increased Risk of Not Achieving Glycemic Target, Increased Glycemic Variability, and Increased Risk of Hypoglycemia for People With Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 193229682092225.	1.3	9
16	COVID-19 Hospitalization in Adults with Type 1 Diabetes: Results from the T1D Exchange Multicenter Surveillance Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e936-e942.	1.8	34
17	HbA1c and Glucose Management Indicator Discordance: A Real-World Analysis. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 253-258.	2.4	47
18	Variables associated with insulin production in persons with type 2 diabetes treated with multiple daily insulin injections. <i>Primary Care Diabetes</i> , 2021, 15, 607-613.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI. <i>Diabetes Care</i> , 2021, 44, 141-149.	4.3	19
20	The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD5). <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 619-630.	2.2	9
21	The Digital/Virtual Diabetes Clinic: The Future Is Now—Recommendations from an International Panel on Diabetes Digital Technologies Introduction. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 146-154.	2.4	79
22	Fifteen-minute Frequency of Glucose Measurements and the Use of Threshold Alarms: Impact on Mitigating Dysglycemia in Critically Ill Patients. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 279-286.	1.3	4
23	Flash CGM Is Associated With Reduced Diabetes Events and Hospitalizations in Insulin-Treated Type 2 Diabetes. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab013.	0.1	39
24	Ranting in 2021: Could This Get Any Worse?. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 157-159.	2.4	3
25	Real-Time Continuous Glucose Monitoring During the Coronavirus Disease 2019 Pandemic and Its Impact on Time in Range. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, S-1-S-7.	2.4	20
26	Time to Follow the Evidence: Glycemic Control and Cardiovascular Benefits of New Diabetes Medications. <i>American Journal of Medicine</i> , 2021, 134, 420-422.	0.6	2
27	Safety Evaluation of the Omnipod® 5 Automated Insulin Delivery System Over Three Months of Use in Adults and Adolescents With Type 1 Diabetes (T1D). <i>Journal of the Endocrine Society</i> , 2021, 5, A671-A672.	0.1	0
28	Characteristics of Continuous Glucose Monitoring Metrics in Persons with Type 1 and Type 2 Diabetes Treated with Multiple Daily Insulin Injections. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 425-433.	2.4	3
29	New Medications for the Treatment of Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, S-185-S-197.	2.4	0
30	Temporal Relationship of Glycemia With Cardiac Arrhythmias in Patients With Type 2 Diabetes and CKD. <i>American Journal of Kidney Diseases</i> , 2021, 77, 988-990.	2.1	2
31	Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. <i>Diabetes Care</i> , 2021, 44, 1630-1640.	4.3	133
32	The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> , 2021, 44, 2589-2625.	4.3	244
33	Insulin Access and Cost at 100 Years: What Would Dr. Banting Think?. <i>Med</i> , 2021, 2, 1002-1004.	2.2	1
34	The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetologia</i> , 2021, 64, 2609-2652.	2.9	128
35	Integrating Continuous Glucose Monitoring Into Clinical Practices and Patients' Lives. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, S-72-S-80.	2.4	11
36	Ranting in 2020: Reflecting About the Past and the Future (with Concerns About the Present). <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 69-71.	2.4	2

#	ARTICLE	IF	CITATIONS
37	Transition of Patients to and from Insulin Degludec: A Clinical Challenge. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2294-e2298.	1.8	7
38	The Impact of COVID-19 on CGM Use in the Hospital. <i>Diabetes Care</i> , 2020, 43, 2628-2630.	4.3	17
39	Response to Letter to the Editor: "Trends in Endocrinology Fellowship Recruitment: Reasons for Concern and Possible Interventions" <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3045-e3046.	1.8	0
40	Driving Safety in Adolescents and Young Adults With Type 1 Diabetes. <i>Diabetes Spectrum</i> , 2020, 33, 352-357.	0.4	5
41	Use of Personal Continuous Glucose Monitoring Device Is Associated With Reduced Risk of Hypoglycemia in a 16-Week Clinical Trial of People With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion. <i>Journal of Diabetes Science and Technology</i> , 2020, , 193229682095766.	1.3	3
42	Continuous Glucose Monitoring and Use of Alternative Markers To Assess Glycemia in Chronic Kidney Disease. <i>Diabetes Care</i> , 2020, 43, 2379-2387.	4.3	35
43	The Evolution of Insulin and How it Informs Therapy and Treatment Choices. <i>Endocrine Reviews</i> , 2020, 41, 733-755.	8.9	116
44	A Pilot Study of the Feasibility and Accuracy of Inpatient Continuous Glucose Monitoring. <i>Diabetes Care</i> , 2020, 43, e168-e169.	4.3	36
45	Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2397.	3.8	191
46	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2020, 382, 2493-2503.	13.9	228
47	Trends in the Endocrinology Fellowship Recruitment: Reasons for Concern and Possible Interventions. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1701-1706.	1.8	29
48	Commercially Available Insulin Products Demonstrate Stability Throughout the Cold Supply Chain Across the U.S.. <i>Diabetes Care</i> , 2020, 43, 1360-1362.	4.3	4
49	The Association Between HbA1c and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4). <i>Diabetes Care</i> , 2020, 43, 2017-2024.	4.3	34
50	New Medications for the Treatment of Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, S-149-S-173.	2.4	2
51	Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000991.	1.2	87
52	Managing New-Onset Type 1 Diabetes During the COVID-19 Pandemic: Challenges and Opportunities. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 431-439.	2.4	126
53	Using Insulin to Treat Poorly Controlled Type 2 Diabetes in 2020. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2419.	3.8	9
54	Towards Prediction of Type 1 Diabetes Patients Who Fail to Achieve Glycemic Target. <i>Studies in Health Technology and Informatics</i> , 2020, 270, 1413-1414.	0.2	0

#	ARTICLE	IF	CITATIONS
55	Optimizing Postprandial Glucose Management in Adults With Insulin-Requiring Diabetes: Report and Recommendations. <i>Journal of the Endocrine Society</i> , 2019, 3, 1942-1957.	0.1	16
56	Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections. <i>Diabetes Therapy</i> , 2019, 10, 2115-2130.	1.2	15
57	Ranting in 2019: Are Things Improving?. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 59-61.	2.4	2
58	Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. <i>Diabetes Care</i> , 2019, 42, 1593-1603.	4.3	2,101
59	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinolâ€™Rationale, Design, and Baseline Data. <i>Diabetes Care</i> , 2019, 42, 1454-1463.	4.3	39
60	Hypoglycemia in People with Type 2 Diabetes and CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 844-853.	2.2	28
61	Evidence supports prediabetes treatment. <i>Science</i> , 2019, 364, 341-342.	6.0	18
62	The Future of the GLP-1 Receptor Agonists. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1457.	3.8	15
63	Glycemic Metrics and Targets in Kidney Disease. , 2019, , 39-48.		0
64	Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1520-1574.	1.8	305
65	Connecting the Dots: Validation of Time in Range Metrics With Microvascular Outcomes. <i>Diabetes Care</i> , 2019, 42, 345-348.	4.3	36
66	Self-Monitoring of Blood Glucose. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, S-4-S-12.	2.4	2
67	Flash Continuous Glucose Monitoring: Implications for Use of Continuous Data in Daily Diabetes Management. <i>Diabetes Spectrum</i> , 2019, 32, 355-367.	0.4	5
68	Using Flash Continuous Glucose Monitoring in Primary Practice. <i>Clinical Diabetes</i> , 2019, 37, 150-161.	1.2	13
69	Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes. <i>Journal of Clinical Hypertension</i> , 2019, 21, 105-115.	1.0	12
70	Clinically significant cognitive impairment in older adults with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 91-97.	1.2	56
71	Clinical Diabetes Centers of Excellence: A Model for Future Adult Diabetes Care. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 809-812.	1.8	6
72	A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3). <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 274-284.	2.4	88

#	ARTICLE	IF	CITATIONS
73	Does Time-in-Range Matter? Perspectives From People With Diabetes on the Success of Current Therapies and the Drivers of Improved Outcomes. <i>Clinical Diabetes</i> , 2018, 36, 112-119.	1.2	75
74	Diabetic Kidney Disease: Is There a Role for Glycemic Variability?. <i>Current Diabetes Reports</i> , 2018, 18, 13.	1.7	13
75	Self-Monitoring of Blood Glucose. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, S-3-S-12.	2.4	9
76	Ranting in 2018: Are We Making Progress?. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 91-93.	2.4	0
77	Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 65-79.	1.2	24
78	Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3). <i>BMJ Open Diabetes Research and Care</i> , 2018, 6, e000464.	1.2	18
79	In Response to Carter and Heinemann: Insulin Concentration in Vials Randomly Purchased in Pharmacies in the United States: Considerable Loss in the Cold Supply Chain. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 890-891.	1.3	10
80	Glycemic Variability Percentage: A Novel Method for Assessing Glycemic Variability from Continuous Glucose Monitor Data. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 6-16.	2.4	64
81	Impact of the 2013 National Rollout of CMS Competitive Bidding Program: The Disruption Continues. <i>Diabetes Care</i> , 2018, 41, 949-955.	4.3	4
82	Clinical Implications of Real-time and Intermittently Scanned Continuous Glucose Monitoring. <i>Diabetes Care</i> , 2018, 41, 2265-2274.	4.3	120
83	Advances in Glucose Monitoring and Automated Insulin Delivery: Supplement to Endocrine Society Clinical Practice Guidelines. <i>Journal of the Endocrine Society</i> , 2018, 2, 1214-1225.	0.1	16
84	Why Are We Failing to Address the Issue of Access to Insulin? A National and Global Perspective. <i>Diabetes Care</i> , 2018, 41, 1125-1131.	4.3	46
85	Health Care Spending on Diabetes in the U.S., 1996â€“2013. <i>Diabetes Care</i> , 2018, 41, 1423-1431.	4.3	24
86	Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment. <i>Current Diabetes Reports</i> , 2018, 18, 48.	1.7	30
87	Brief Commentary: Confusing Treatment Guidelines for Patients With Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2018, 169, 253.	2.0	4
88	The Hybrid Closed-Loop System: Evolution and Practical Applications. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, S2-16-S2-23.	2.4	65
89	Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 379.	3.8	520
90	Ranting in 2017: Is It Working?. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 69-72.	2.4	0

#	ARTICLE	IF	CITATIONS
91	REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes. <i>Diabetes Care</i> , 2017, 40, 538-545.	4.3	230
92	Self-Monitoring of Blood Glucose. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, S-3-S-10.	2.4	1
93	Serum cystatin C in youth with diabetes: The SEARCH for diabetes in youth study. <i>Diabetes Research and Clinical Practice</i> , 2017, 130, 258-265.	1.1	6
94	Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 391-399.	2.4	45
95	Human Insulin for Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 23.	3.8	67
96	The First Hybrid Closed-Loop Insulin Pump: Will It Meet Its Potential?. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 140-141.	2.4	3
97	Professional flash continuous glucose monitoring as a supplement to A1C in primary care. <i>Postgraduate Medicine</i> , 2017, 129, 781-790.	0.9	18
98	Type 1 Diabetes in the Hospital: What Do We Know About Glucose Control?. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 555-556.	2.4	0
99	Professional Flash Continuous Glucose Monitoring with Ambulatory Glucose Profile Reporting to Supplement A1c: Rationale and Practical Implementation. <i>Endocrine Practice</i> , 2017, 23, 1333-1344.	1.1	20
100	Application of Glycemic Variability Percentage: Implications for Continuous Glucose Monitor Utilization and Analysis of Artificial Pancreas Data. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 699-706.	2.4	6
101	International Consensus on Use of Continuous Glucose Monitoring. <i>Diabetes Care</i> , 2017, 40, 1631-1640.	4.3	1,376
102	A Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System for the Management of Adults With Diabetes. <i>Journal of the Endocrine Society</i> , 2017, 1, 1445-1460.	0.1	75
103	Progression To Insulin Dependence Post-Treatment With Immune Checkpoint Inhibitors In Pre-Existing Type 2 Diabetes. <i>AACE Clinical Case Reports</i> , 2017, 3, e153-e157.	0.4	10
104	Self-Monitoring of Blood Glucose. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, S-3-S-9.	2.4	6
105	American Association Of Clinical Endocrinologists And American College Of Endocrinology 2016 Outpatient Glucose Monitoring Consensus Statement. <i>Endocrine Practice</i> , 2016, 22, 231-262.	1.1	97
106	Continuous Glucose Monitoring: A Consensus Conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. <i>Endocrine Practice</i> , 2016, 22, 1008-1021.	1.1	151
107	Decisional practices and patterns of intraoperative glucose management in an academic medical center. <i>Journal of Clinical Anesthesia</i> , 2016, 32, 214-223.	0.7	6
108	Improving Patient Experience With Insulin Infusion Sets. <i>The Diabetes Educator</i> , 2016, 42, 470-484.	2.6	24

#	ARTICLE	IF	CITATIONS
109	Design and Methods of a Randomized Trial of Continuous Glucose Monitoring in Persons With Type 1 Diabetes With Impaired Glycemic Control Treated With Multiple Daily Insulin Injections (GOLD Study). <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 754-761.	1.3	18
110	Diabetes Technologyâ€”Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3922-3937.	1.8	165
111	Response to Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. <i>Diabetes Care</i> 2016;39:973â€”981. <i>Diabetes Care</i> . 2016. 39. e188-e188.	4.3	2
112	Insulin in America: A Right or a Privilege?. <i>Diabetes Spectrum</i> , 2016, 29, 130-132.	0.4	12
113	Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. <i>Diabetes Care</i> , 2016, 39, 1693-1701.	4.3	159
114	Ranting in 2016: A Medical System in Crisis. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 110-112.	2.4	1
115	Unknown Safety and Efficacy of Smartphone Bolus Calculator Apps Puts Patients at Risk for Severe Adverse Outcomes. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 977-980.	1.3	19
116	Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 603-610.	4.3	126
117	Intraoperative blood glucose management: impact of a real-time decision support system on adherence to institutional protocol. <i>Journal of Clinical Monitoring and Computing</i> , 2016, 30, 301-312.	0.7	29
118	Stress Testing of an Artificial Pancreas System With Pizza and Exercise Leads to Improvements in the Systemâ€™s Fuzzy Logic Controller. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 1253-1259.	1.3	26
119	American Association of Clinical Endocrinologists and American College of Endocrinology â€” Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan â€” 2015 â€” Executive Summary. <i>Endocrine Practice</i> , 2015, 21, 413-437.	1.1	359
120	1,5-Anhydroglucitol and Neonatal Complications in Pregnancy Complicated by Diabetes. <i>Endocrine Practice</i> , 2015, 21, 725-733.	1.1	15
121	Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodiumâ€”Glucose Cotransporter 2 Inhibition. <i>Diabetes Care</i> , 2015, 38, 1687-1693.	4.3	645
122	Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1558-1566.	4.3	32
123	Glycemic Variability and Diabetes Complications: Does It Matter? Of Course It Does!. <i>Diabetes Care</i> , 2015, 38, 1610-1614.	4.3	206
124	Costs Associated With Using Different Insulin Preparations. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 665.	3.8	24
125	Antiâ€”PD-1 and Antiâ€”PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, e137-e138.	4.3	138
126	Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research. <i>Diabetes Care</i> , 2015, 38, 1627-1633.	4.3	28

#	ARTICLE	IF	CITATIONS
127	Management of Hyperglycemia in Diabetic Kidney Disease. <i>Diabetes Spectrum</i> , 2015, 28, 214-219.	0.4	15
128	Diabetes Management. <i>Medical Clinics of North America</i> , 2015, 99, xvii-xviii.	1.1	1
129	Interference of Intravenous Vitamin C With Blood Glucose Testing. <i>Diabetes Care</i> , 2014, 37, e93-e94.	4.3	24
130	A Short-Acting GLP-1 Analog or Prandial Insulin to Supplement Basal Insulin? "Moving Toward Personalized Management of Type 2 Diabetes Mellitus. <i>Postgraduate Medicine</i> , 2014, 126, 135-144.	0.9	10
131	Diabetes and Driving. <i>Diabetes Care</i> , 2014, 37, S97-S103.	4.3	51
132	Diabetes Care Entering 2014: More Ranting. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, iii-iv.	2.4	2
133	Diabetic Kidney Disease: A Report From an ADA Consensus Conference. <i>American Journal of Kidney Diseases</i> , 2014, 64, 510-533.	2.1	439
134	Diabetic Kidney Disease: A Report From an ADA Consensus Conference. <i>Diabetes Care</i> , 2014, 37, 2864-2883.	4.3	781
135	Glycemic Management in a Patient with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2013, 369, 1370-1372.	13.9	7
136	Evidence of a Strong Association Between Frequency of Self-Monitoring of Blood Glucose and Hemoglobin A1c Levels in T1D Exchange Clinic Registry Participants. <i>Diabetes Care</i> , 2013, 36, 2009-2014.	4.3	415
137	Recommendations for Standardizing Glucose Reporting and Analysis to Optimize Clinical Decision Making in Diabetes: The Ambulatory Glucose Profile. <i>Journal of Diabetes Science and Technology</i> , 2013, 7, 562-578.	1.3	104
138	Understanding Low Sugar from NICE-SUGAR. <i>New England Journal of Medicine</i> , 2012, 367, 1150-1152.	13.9	26
139	Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2174-2181.	4.3	69
140	Using Multiple Measures of Glycemia to Support Individualized Diabetes Management: Recommendations for Clinicians, Patients, and Payers. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 973-983.	2.4	16
141	How to Best Manage Glycemia and Non-Glycemia During the Time of Acute Myocardial Infarction. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, S-22-S-32.	2.4	14
142	Motherhood, Apple Pie, Hemoglobin A _{1c} , and the DCCT. <i>Endocrine Practice</i> , 2012, 18, 78-84.	1.1	2
143	Motherhood, Apple Pie, Hemoglobin A _{1c} , and the DCCT. <i>Endocrine Practice</i> , 2012, 18, 78-84.	1.1	8
144	Patient Factors Associated with Glucagonlike Peptide 1 Receptor Agonist use with and without Insulin. <i>Endocrine Practice</i> , 2011, 17, 707-716.	1.1	9

#	ARTICLE	IF	CITATIONS
145	Reexamining Metrics for Glucose Control. JAMA - Journal of the American Medical Association, 2011, 305, 1132.	3.8	35
146	Hemoglobin A1c and Mean Glucose in Patients With Type 1 Diabetes. Diabetes Care, 2011, 34, 540-544.	4.3	51
147	Designing mobile support for glycemic control in patients with diabetes. Journal of Biomedical Informatics, 2010, 43, S37-S40.	2.5	46
148	How to proceed with glucose monitoring accuracy? An issue that requires immediate attention. Journal of Diabetes, 2010, 2, 225-226.	0.8	1
149	Beyond Hemoglobin A_{1c}: Need for Additional Markers of Risk for Diabetic Microvascular Complications. JAMA - Journal of the American Medical Association, 2010, 303, 2291.	3.8	149
150	Practical Pearls in Insulin Pump Therapy. Diabetes Technology and Therapeutics, 2010, 12, S-23-S-27.	2.4	10
151	Insulin Delivery Devices—Pumps and Pens. Diabetes Technology and Therapeutics, 2010, 12, S-115-S-116.	2.4	3
152	Continuous Glucose Monitoring: Understanding Our Current Culture. Diabetes Technology and Therapeutics, 2009, 11, S-131-S-132.	2.4	2
153	Sliding Scale Insulin—Time to Stop Sliding. JAMA - Journal of the American Medical Association, 2009, 301, 213.	3.8	115
154	Realistic Expectations and Practical Use of Continuous Glucose Monitoring for the Endocrinologist. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2232-2238.	1.8	82
155	The Contribution of Malglycemia to Mortality among Allogeneic Hematopoietic Cell Transplant Recipients. Biology of Blood and Marrow Transplantation, 2009, 15, 344-351.	2.0	80
156	American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control. Diabetes Care, 2009, 32, 1119-1131.	4.3	1,115
157	Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes. New England Journal of Medicine, 2008, 359, 1464-1476.	13.9	1,369
158	The Utility and Recent Advances in Self-Monitoring of Blood Glucose in Type 1 Diabetes. Diabetes Technology and Therapeutics, 2008, 10, S-43-S-50.	2.4	11
159	Arguments Against the Use of Inhaled Insulin. Diabetes Technology and Therapeutics, 2007, 9, S-111-S-114.	2.4	6
160	Inpatient Diabetes: Review of Data from the Cardiac Care Unit. Endocrine Practice, 2006, 12, 27-34.	1.1	7
161	New Insulin Infusion Protocol Improves Blood Glucose Control in Hospitalized Patients Without Increasing Hypoglycemia. Joint Commission Journal on Quality and Patient Safety, 2005, 31, 141-147.	0.4	57
162	Insulin Analogues. New England Journal of Medicine, 2005, 352, 174-183.	13.9	720

#	ARTICLE	IF	CITATIONS
163	Should minimal blood glucose variability become the gold standard of glycemic control?. Journal of Diabetes and Its Complications, 2005, 19, 178-181.	1.2	345
164	Intensifying insulin therapy in patients with type 2 diabetes mellitus. American Journal of Medicine, 2005, 118, 21-26.	0.6	31
165	Glycemic Variability: It's Not Just About A1C Anymore!. Diabetes Technology and Therapeutics, 2005, 7, 780-783.	2.4	109
166	Optimal initiation of insulin in type 2 diabetes. MedGenMed: Medscape General Medicine, 2005, 7, 49.	0.2	6
167	Effect of Insulin Therapy on Nonglycemic Variables During Acute Illness. Endocrine Practice, 2004, 10, 63-70.	1.1	23
168	Treatment of patients with severe insulin deficiency. American Journal of Medicine, 2004, 116, 17-22.	0.6	9
169	The changing faces of diabetes. Primary Care - Clinics in Office Practice, 2003, 30, 499-510.	0.7	3
170	The Burden of Diabetes (Care). Diabetes Care, 2003, 26, 1613-1614.	4.3	16
171	A multifaceted intervention in support of diabetes treatment guidelines: a cont trial. Diabetes Research and Clinical Practice, 2002, 58, 27-36.	1.1	42
172	Severe insulin resistance in a patient with type 1 diabetes and stiff-man syndrome treated with insulin lispro. Diabetes Research and Clinical Practice, 1998, 41, 197-202.	1.1	26
173	Insulin analogues. Postgraduate Medicine, 1997, 101, 58-70.	0.9	36
174	Reduced Plasma Peroxyl Radical Trapping Capacity and Increased Susceptibility of LDL to Oxidation In Poorly Controlled IDDM. Diabetes, 1994, 43, 1010-1014.	0.3	243
175	Increased symptoms of hypoglycaemia in the standing position in insulin-dependent diabetes mellitus. Clinical Science, 1991, 80, 583-586.	1.8	16
176	Higher Glycemic Thresholds for Symptoms During \hat{A} -Adrenergic Blockade in IDDM. Diabetes, 1991, 40, 1177-1186.	0.3	61
177	Failure of Nocturnal Hypoglycemia to Cause Daytime Hyperglycemia in Patients With IDDM. Diabetes Care, 1990, 13, 133-142.	4.3	31